Description
Buy ACE-031 Peptide Online (Research Use Only)
ACE-031 peptide is a myostatin inhibitor widely studied in experimental research focused on muscle growth, body composition, and tissue signaling pathways. Also known as ActRIIB-IgG1-Fc, it is a fusion protein designed to bind and neutralize myostatin-related activity in laboratory models.
For researchers exploring advanced muscle regulation compounds, ACE-031 is often included in studies examining muscle hypertrophy, bone density signaling, and metabolic modulation pathways.
What is ACE-031?
ACE-031 is a soluble activin type IIB receptor fusion protein that has been studied for its ability to interact with members of the TGF-β superfamily, particularly myostatin (GDF-8).
Myostatin is known as a natural regulator that limits muscle growth. In research settings, ACE-031 is explored for its potential to bind circulating myostatin, thereby preventing receptor activation and allowing increased muscle signaling activity in experimental models.
👉 Learn more related compounds:
- BPC-157 5mg
- TB-500 Thymosin Beta-4 Acetate 5mg
- CJC-1295 with DAC 5mg
Research-Observed Areas of Interest
ACE-031 is studied in preclinical and laboratory environments for the following:
- Muscle hypertrophy signaling pathways
- Lean mass and skeletal muscle volume research
- Fat metabolism and energy regulation models
- Bone density and trabecular structure studies
- Myostatin inhibition mechanisms in TGF-β pathways
These findings are strictly based on experimental models and are not approved clinical outcomes.
ACE-031 Peptide Benefits (Research Context)
In scientific literature, ACE-031 has been associated with:
- Increased lean muscle mass in animal models
- Enhanced muscle volume and growth signaling
- Potential reduction in fat accumulation pathways
- Improved bone density markers in research studies
- Modulation of muscle performance and contractile force
How ACE-031 Works (Scientific Overview)
ACE-031 functions by acting as a decoy receptor for myostatin and related ligands. Instead of binding to muscle receptors (ActR2B), these ligands attach to ACE-031, reducing their inhibitory effect on muscle growth signaling.
This process is studied for its role in:
- Smad2/3 signaling suppression
- Muscle cell satellite activation
- Growth factor pathway modulation
ACE-031 Dosage (Research Context Only)
There is no approved human dosage. In laboratory discussions, researchers reference the following:
- Long half-life (~10–15 days in studies)
- Single or spaced dosing models in experimental designs
- Dosing varies depending on research objective and model type
ACE-031 Buy Online USA
Researchers looking for ACE-031 in the United States typically search for verified laboratory suppliers offering:
- Third-party tested peptides
- Research-grade purity certification
- Batch traceability and COA documentation
Explore related research compounds:
- Semaglutide 10mg x 10 Vials
- GHK-Cu 100mg x 10 Vials
- Ipamorelin 10mg x 10 Vials
ACE-031 For Sale China Wholesale
Bulk sourcing options are commonly requested for laboratory and institutional research supply chains. Typical wholesale considerations include the following:
- GMP manufacturing standards
- Export compliance documentation
- Bulk lyophilized vial packaging
- Research-only labeling requirements
Related wholesale research categories:
- All Peptides
- Peptide Research Compounds
Buy ACE-031 Online (US States Coverage)
ACE-031 is commonly searched for availability across multiple U.S. regions, including:
- California
- Texas
- Florida
- New York
- Illinois
- Arizona
Researchers should ensure compliance with local regulations before ordering any peptide compounds.
Product Specifications
- Molecular Formula: C3418H5188N928O1062S38
- Molecular Weight: 77,489.82 g/mol
- Form: Lyophilized powder
- Storage: 2–8°C refrigerated
- Use: Research and laboratory only
Important Disclaimer
The ACE-031 peptide is strictly intended for laboratory and research use only. It is not approved for human consumption, medical treatment, or diagnostic use. Buyers are responsible for ensuring compliance with local laws and research regulations.
References
- Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve. 2017;55(4):458–464. https://pubmed.ncbi.nlm.nih.gov/27462804/
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. 1997;387(6628):83–90. https://pubmed.ncbi.nlm.nih.gov/9139826/
